Related Experiment Video
Updated: Dec 23, 2025
Recognition of Epidermal Transglutaminase by IgA and Tissue Transglutaminase 2 Antibodies in a Rare Case of Rhesus Dermatitis
Published on: December 15, 2011
Erdheim-Chester disease
Gordon Starkebaum1, Paul Hendrie2
1University of Washington, Division of Rheumatology, 1959 NE Pacific St., Box 356428, Seattle, WA, 98195-6428, USA.
Insights
Erdheim-Chester disease (ECD) is a rare multi-system disorder diagnosed through clinical, imaging, and pathology. Identifying MAPK pathway mutations is crucial for diagnosis and guides targeted therapy for this clonal myeloid disorder.
Area of Science:
- Oncology
- Genetics
- Pathology
Background:
- Erdheim-Chester disease (ECD) is a rare multi-system disorder.
- Diagnosis and treatment necessitate integrating clinical, imaging, and pathology data.
- ECD is recognized as a clonal myeloid disorder driven by MAPK pathway-activating mutations.
Purpose of the Study:
- To outline the diagnostic criteria for Erdheim-Chester disease.
- To highlight the role of genetic mutations in ECD pathogenesis and differential diagnosis.
- To emphasize the importance of MAPK pathway mutational status in guiding therapy.
Main Methods:
- Review of clinical, imaging, and histopathologic features for diagnosis.
- Detection of somatic MAPK pathway mutations (e.g., BRAF, RAS) via genetic analysis.
- Evaluation of therapeutic strategies, including MAPK pathway inhibition.
Main Results:
- Diagnosis requires characteristic histopathology, clinical findings, and often sclerosing long bone involvement.
- Somatic MAPK pathway mutations aid in differentiating ECD from other histiocytic neoplasms.
- Genetic analysis of BRAF and RAS status is critical for therapeutic decisions.
Conclusions:
- ECD diagnosis is multi-faceted, requiring integrated data and genetic profiling.
- Targeted therapy, particularly MAPK inhibition, is guided by specific genetic mutations.
- Prospective therapeutic trials are vital for advancing ECD treatment.
Abstract:
Erdheim-Chester disease (ECD) is a rare but increasingly recognized multi-system disorder. Its diagnosis and treatment require integration of clinical information, imaging studies, and pathology studies. Of note, ECD can now be defined as a clonal myeloid disorder due to mutations which activate mitogen-activated protein kinase (MAPK) pathways and where an inflammatory milieu is important in the pathogenesis and clinical manifestations of the disease. Biopsy demonstrating characteristic histopathologic features in addition to clinical and radiographic features, most often sclerosing long bone involvement, is required to establish a diagnosis. Detection of somatic MAPK pathway mutations can also assist in the differential diagnosis of ECD and related histiocytic neoplasms. Also, genetic analysis establishing BRAF and RAS mutational status is critical in all ECD patients, as these features will impact therapy with MAPK inhibition. Therapy is recommended at diagnosis in all patients, except for those patients with minimally symptomatic disease. Prospective therapeutic trials are essential to furthering therapeutic progress in ECD.
Related Concept Videos
01:23Rheumatic Heart Disease I: Introduction
01:25Endocarditis II: Clinical Features of Infective Endocarditis
01:22Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
01:23Skin Diseases and Disorders
Gram-positive Staphylococcus spp. and Streptococcus spp. are responsible for many of the most common skin infections. However, many...
01:30Other Disorders of Digestive System
01:25Immunodeficiency Diseases
There are three main causes of immunodeficiency...